Host-Derived Lipids from Tuberculous Pleurisy Impair Macrophage Microbicidal-Associated Metabolic Activity.


Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
29 12 2020
Historique:
received: 28 02 2020
revised: 18 10 2020
accepted: 02 12 2020
entrez: 30 12 2020
pubmed: 31 12 2020
medline: 14 10 2021
Statut: ppublish

Résumé

Mycobacterium tuberculosis (Mtb) regulates the macrophage metabolic state to thrive in the host, yet the responsible mechanisms remain elusive. Macrophage activation toward the microbicidal (M1) program depends on the HIF-1α-mediated metabolic shift from oxidative phosphorylation (OXPHOS) toward glycolysis. Here, we ask whether a tuberculosis (TB) microenvironment changes the M1 macrophage metabolic state. We expose M1 macrophages to the acellular fraction of tuberculous pleural effusions (TB-PEs) and find lower glycolytic activity, accompanied by elevated levels of OXPHOS and bacillary load, compared to controls. The eicosanoid fraction of TB-PE drives these metabolic alterations. HIF-1α stabilization reverts the effect of TB-PE by restoring M1 metabolism. Furthermore, Mtb-infected mice with stabilized HIF-1α display lower bacillary loads and a pronounced M1-like metabolic profile in alveolar macrophages (AMs). Collectively, we demonstrate that lipids from a TB-associated microenvironment alter the M1 macrophage metabolic reprogramming by hampering HIF-1α functions, thereby impairing control of Mtb infection.

Identifiants

pubmed: 33378679
pii: S2211-1247(20)31536-9
doi: 10.1016/j.celrep.2020.108547
pii:
doi:

Substances chimiques

Eicosanoids 0
HIF1A protein, human 0
Hif1a protein, mouse 0
Hypoxia-Inducible Factor 1, alpha Subunit 0
Lipids 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

108547

Informations de copyright

Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Interests The authors declare no competing interests.

Auteurs

José Luis Marín Franco (JL)

Instituto de Medicina Experimental (IMEX)-CONICET, Academia Nacional de Medicina, Buenos Aires C1425ASU, Argentina; International Associated Laboratory (LIA) CNRS IM-TB/HIV (1167), Buenos Aires, Argentina - Toulouse, France.

Melanie Genoula (M)

Instituto de Medicina Experimental (IMEX)-CONICET, Academia Nacional de Medicina, Buenos Aires C1425ASU, Argentina; International Associated Laboratory (LIA) CNRS IM-TB/HIV (1167), Buenos Aires, Argentina - Toulouse, France.

Dan Corral (D)

Institut de Pharmacologie et de Biologie Structurale, Université de Toulouse, CNRS, UPS, Toulouse 31077, France.

Gabriel Duette (G)

Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires C1121ABG, Argentina.

Malena Ferreyra (M)

Instituto de Medicina Experimental (IMEX)-CONICET, Academia Nacional de Medicina, Buenos Aires C1425ASU, Argentina; International Associated Laboratory (LIA) CNRS IM-TB/HIV (1167), Buenos Aires, Argentina - Toulouse, France.

Mariano Maio (M)

Instituto de Medicina Experimental (IMEX)-CONICET, Academia Nacional de Medicina, Buenos Aires C1425ASU, Argentina.

María Belén Dolotowicz (MB)

Instituto de Medicina Experimental (IMEX)-CONICET, Academia Nacional de Medicina, Buenos Aires C1425ASU, Argentina.

Omar Emiliano Aparicio-Trejo (OE)

Department of Biology, Faculty of Chemistry, National Autonomous University of Mexico (UNAM), Mexico City 04510, Mexico.

Eduardo Patiño-Martínez (E)

Departamento de Biomedicina Molecular, CINVESTAV, Mexico City 07360, Mexico.

Alison Charton (A)

Institut de Pharmacologie et de Biologie Structurale, Université de Toulouse, CNRS, UPS, Toulouse 31077, France.

Arnaud Métais (A)

Institut de Pharmacologie et de Biologie Structurale, Université de Toulouse, CNRS, UPS, Toulouse 31077, France.

Federico Fuentes (F)

Instituto de Medicina Experimental (IMEX)-CONICET, Academia Nacional de Medicina, Buenos Aires C1425ASU, Argentina.

Vanessa Soldan (V)

METi, Centre de Biologie Intégrative, Université de Toulouse, CNRS, UPS, Toulouse 31062, France.

Eduardo José Moraña (EJ)

Instituto Prof. Dr. Raúl Vaccarezza, Hospital de Infecciosas Dr. F.J. Muñiz, Buenos Aires C1282AFE, Argentina.

Domingo Palmero (D)

Instituto Prof. Dr. Raúl Vaccarezza, Hospital de Infecciosas Dr. F.J. Muñiz, Buenos Aires C1282AFE, Argentina.

Matías Ostrowski (M)

Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires C1121ABG, Argentina.

Pablo Schierloh (P)

International Associated Laboratory (LIA) CNRS IM-TB/HIV (1167), Buenos Aires, Argentina - Toulouse, France; Instituto de I+D en Bioingenieria y Bioinformática (IBB)-UNER-CONICET, Entre Ríos 3100, Argentina.

Carmen Sánchez-Torres (C)

Departamento de Biomedicina Molecular, CINVESTAV, Mexico City 07360, Mexico.

Rogelio Hernández-Pando (R)

Department of Pathology, National Institute of Medical Science and Nutrition, Salzador Zubiran, Mexico City 14080, Mexico.

José Pedraza-Chaverri (J)

Department of Biology, Faculty of Chemistry, National Autonomous University of Mexico (UNAM), Mexico City 04510, Mexico.

Yoann Rombouts (Y)

Institut de Pharmacologie et de Biologie Structurale, Université de Toulouse, CNRS, UPS, Toulouse 31077, France.

Denis Hudrisier (D)

Institut de Pharmacologie et de Biologie Structurale, Université de Toulouse, CNRS, UPS, Toulouse 31077, France.

Emilie Layre (E)

Institut de Pharmacologie et de Biologie Structurale, Université de Toulouse, CNRS, UPS, Toulouse 31077, France.

Christel Vérollet (C)

International Associated Laboratory (LIA) CNRS IM-TB/HIV (1167), Buenos Aires, Argentina - Toulouse, France; Institut de Pharmacologie et de Biologie Structurale, Université de Toulouse, CNRS, UPS, Toulouse 31077, France.

Isabelle Maridonneau-Parini (I)

International Associated Laboratory (LIA) CNRS IM-TB/HIV (1167), Buenos Aires, Argentina - Toulouse, France; Institut de Pharmacologie et de Biologie Structurale, Université de Toulouse, CNRS, UPS, Toulouse 31077, France.

Olivier Neyrolles (O)

International Associated Laboratory (LIA) CNRS IM-TB/HIV (1167), Buenos Aires, Argentina - Toulouse, France; Institut de Pharmacologie et de Biologie Structurale, Université de Toulouse, CNRS, UPS, Toulouse 31077, France.

María Del Carmen Sasiain (MDC)

Instituto de Medicina Experimental (IMEX)-CONICET, Academia Nacional de Medicina, Buenos Aires C1425ASU, Argentina; International Associated Laboratory (LIA) CNRS IM-TB/HIV (1167), Buenos Aires, Argentina - Toulouse, France.

Geanncarlo Lugo-Villarino (G)

International Associated Laboratory (LIA) CNRS IM-TB/HIV (1167), Buenos Aires, Argentina - Toulouse, France; Institut de Pharmacologie et de Biologie Structurale, Université de Toulouse, CNRS, UPS, Toulouse 31077, France. Electronic address: lugo@ipbs.fr.

Luciana Balboa (L)

Instituto de Medicina Experimental (IMEX)-CONICET, Academia Nacional de Medicina, Buenos Aires C1425ASU, Argentina; International Associated Laboratory (LIA) CNRS IM-TB/HIV (1167), Buenos Aires, Argentina - Toulouse, France. Electronic address: luciana_balboa@hotmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH